MAP2K7 and hypertrophic cardiomyopathy: One approach is the targeted inhibition of the rat sarcoma (Ras)/Mapk pathway, as demonstrated in a study that involved using trametinib, a MEK inhibitor, in infants with severe hypertrophic cardiomyopathy (HCM) and PVS associated with NS [179].